8-K
filed February 6, 2023, 6:59 PM ET
CIK 0001709401
regulatory
confidence high
sentiment negative
materiality 0.90
Rubius Therapeutics, Inc.: Nasdaq/NYSE listing notice — Rubius receives Nasdaq delisting notice; three directors resign, CEO extends term
Rubius Therapeutics, Inc.
- Nasdaq notified Rubius of delisting on Feb 15, 2023 for bid price <$1.00 and public shell status; company to request hearing.
- CEO Dannielle Appelhans extends employment until March 3, 2023 (previously Jan 31); may provide consulting.
- Chief Scientific Officer Laurence Turka stepped down Jan 31, 2023; remains as consultant.
- Three directors (Cuss, Rosenblatt, Schaffert) resigned Jan 31; no disagreement with company.
- Company continues strategic review; no assurance of value realization for stockholders.
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
Rubius Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5101).
- Exchange
- nasdaq
- Notice
- delisting notice
- Deficiency
- minimum bid price
- Rules
- 5450(a)(1), 5101
Exact text from the filing
February 6, 2023, Rubius Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) as of January 23, 2023, and the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, the Company would be delisted at the opening of business on February 15, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Michael Rosenblatt resigned as Director at Rubius Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On January 31, 2023, Francis Cuss, M.B., B. Chir., FRCP, Michael Rosenblatt, M.D. and Susanne Schaffert, Ph.D. , each notified the Company of their respective resignations as members of the Company’s board of directors, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Susanne Schaffert resigned as Director at Rubius Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On January 31, 2023, Francis Cuss, M.B., B. Chir., FRCP, Michael Rosenblatt, M.D. and Susanne Schaffert, Ph.D. , each notified the Company of their respective resignations as members of the Company’s board of directors, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Laurence Turka departed as Chief Scientific Officer at Rubius Therapeutics, Inc..
- Action
- stepped down
- Role
- Chief Scientific Officer
Exact text from the filing
On January 31, 2023, Laurence Turka, M.D., stepped down from his position as Chief Scientific Officer and Head of Research and Translational Medicine of the Company on the terms previously disclosed in the November 8-K.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Francis Cuss resigned as Director at Rubius Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On January 31, 2023, Francis Cuss, M.B., B. Chir., FRCP, Michael Rosenblatt, M.D. and Susanne Schaffert, Ph.D. , each notified the Company of their respective resignations as members of the Company’s board of directors, effective immediately.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.